Core Insights - The recombinant protein concept sector rose by 2.66%, ranking 7th among concept sectors, with 49 stocks increasing in value, including *ST Wanfang, which hit the daily limit, and notable gainers such as Saiseng Pharmaceutical, Kefu Medical, and Rejing Bio, which rose by 9.16%, 7.86%, and 6.96% respectively [1][2] Market Performance - The top-performing concept sectors today included Tonghuashun Fruit Index (+3.40%), Cell Immunotherapy (+3.18%), and PEEK Materials (+3.06%), while the sectors with declines included Military Equipment Restructuring (-1.88%) and Transgenic (-1.07%) [2] - The recombinant protein sector saw a net inflow of 389 million yuan, with 37 stocks receiving net inflows, and 6 stocks attracting over 30 million yuan in net inflows, led by Tonghua Dongbao with 48.94 million yuan [2][3] Fund Flow Analysis - The stocks with the highest net inflow ratios included *ST Wanfang (31.91%), Furuida (13.74%), and North China Pharmaceutical (12.46%) [3] - The top stocks in the recombinant protein sector by net inflow included Tonghua Dongbao (4.55% increase, 48.94 million yuan inflow), Beida Pharmaceutical (-0.77%, 46.41 million yuan inflow), and Hite Bio (5.13%, 35.56 million yuan inflow) [3][4]

证券代码：600867 证券简称：通化东宝 公告编号：2025-062 通化东宝药业股份有限公司关于 2025 年员工持股计划第一次持有人会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 通化东宝药业股份有限公司（以下简称"公司"、"通化东宝"）2025 年员工 持股计划第一次持有人会议于 2025 年 10 月 15 日以通讯方式召开，会议通知已 于 2025 年 10 月 10 日通过书面或电子邮件的方式送达各位持有人。本次会议由 公司董事长（代行董事会秘书）李佳鸿先生召集和主持，出席本次会议的持有人 共 75 人，代表公司 2025 年员工持股计划份额合计 3,985.41 万份，占 2025 年员 工持股计划总份额的 100%。 本次会议召开符合有关法律法规、规范性文件以及《通化东宝 2025 年员工 持股计划》《通化东宝 2025 年员工持股计划管理办法》的相关规定。经与会持有 人认真审议，会议形成了如下决议： 二、会议审议情况 （一）审议通过了《关于设立 2025 年员工持股计划管理 ...

Group 1 - The core point of the news is that Tonghua Dongbao's stock price increased by 5.25% to 9.02 CNY per share, with a trading volume of 436 million CNY and a turnover rate of 2.53%, resulting in a total market capitalization of 17.666 billion CNY [1] - Tonghua Dongbao Pharmaceutical Co., Ltd. is primarily engaged in the production of biological products, with 90.29% of its revenue coming from raw materials and formulations, while medical devices account for 6.07%, traditional Chinese medicine and chemical drugs for 2.24%, and other sources for 1.27% [1] - The company was established on December 28, 1992, and went public on August 24, 1994, with its main products including hard capsules, tablets (including hormone types), granules, small-volume injections, and raw materials (recombinant human insulin) [1] Group 2 - Among the top ten circulating shareholders of Tonghua Dongbao, a fund under Yinhua Fund holds a position, having reduced its holdings by 6.308 million shares in the second quarter, now holding 11.0713 million shares, which is 0.57% of the circulating shares [2] - The fund, named Innovation Medicine (159992), has achieved a year-to-date return of 28.18%, ranking 1649 out of 4220 in its category, and a one-year return of 22.33%, ranking 2081 out of 3857 [2] - The fund manager, Ma Jun, has a tenure of 13 years and 45 days, with a total fund size of 33.304 billion CNY, achieving a best return of 144.61% and a worst return of -75.62% during his tenure [3]

Summary of Conference Call Notes Industry Overview - **Industry**: China Healthcare - **Quarter**: 3Q25 Key Companies and Revenue Growth Companies with Higher Revenue Growth 1. **United Imaging** - Expected revenue growth: **44% YoY** in 3Q25 - Growth driven by improved hospital bidding data in China [1][6] 2. **Lepu** - Expected revenue growth: **38% YoY** in 3Q25 - Growth factors: - Low base effect from 3Q24 due to "Four Same" policy impacting pharmaceutical business - Incremental revenue from consumer healthcare segment, particularly medical aesthetics [1][6] 3. **Gan & Lee Pharmaceuticals** - Expected revenue growth: **23% YoY** in 3Q25 - Benefits from insulin VBP renewal and progress in overseas expansion [1][6] Companies Under Pressure 1. **Zhifei** - Currently in the trough of its revenue cycle - Revenue expected to decline by **30% YoY** in 3Q25 - Increased competition following Wantai's launch of a 9-valent HPV vaccine - Offering discounts to accelerate inventory destocking [2][6] 2. **ICL Companies (Kingmed and Dian Diagnostics)** - Expected to post negative revenue growth in 3Q25 - Industry pricing pressure has stabilized, indicating potential for positive growth in 4Q25 [2][6] Financial Estimates and Changes - **Tonghua Dongbao**: Revised annual earnings estimates upward due to market share gains post-insulin VBP renewal [7] - **Kelun**: Revised net profit estimates downward due to ongoing price war in the API industry, while revenue estimates remain unchanged [7][10] Detailed Financial Estimates Exhibit 1: Revenue and Earnings Growth Preview - **United Imaging**: Revenue from **1,621 million** to **2,327 million** (44% YoY) - **Lepu**: Revenue from **1,402 million** to **1,937 million** (38% YoY) - **Gan & Lee**: Revenue from **930 million** to **1,140 million** (23% YoY) - **Zhifei**: Revenue from **4,528 million** to **3,177 million** (-30% YoY) [6] Exhibit 2: Updated Estimates for Tonghua Dongbao (2025E to 2027E) - **Revenue**: Increased from **2,612 million** to **2,689 million** (3.0% change) - **Net Profit**: Increased from **401 million** to **408 million** (1.5% change) [8] Exhibit 3: Updated Estimates for Kelun (2025E to 2027E) - **Revenue**: Remains at **19,029 million** (0.0% change) - **Net Profit**: Decreased from **2,791 million** to **2,686 million** (-3.8% change) [10] Risks and Methodology - **Mindray**: Target price of **Rmb314** with risks including VBP impacts and market penetration challenges [12][13] - **SNIBE**: Target price of **Rmb73** with risks from competition and policy changes [14] - **Hualan**: Target price of **Rmb19** with risks from regulatory changes and competition [15] - **Tonghua Dongbao**: Neutral rating with target price of **Rmb9**, risks from product sales ramp-up and competition [17] - **Kelun**: Neutral rating with target price of **Rmb38**, risks from API price declines [18] Conclusion - The China healthcare sector is experiencing varied growth dynamics, with certain companies like United Imaging and Lepu showing strong revenue growth, while others like Zhifei face significant challenges. The financial estimates reflect these trends, with adjustments made based on market conditions and competitive pressures.

Core Insights - Tonghua Dongbao Pharmaceutical Co., Ltd. has received approval for its core product, Insulin Glargine injection, from Myanmar's national drug regulatory authority, marking a significant entry into the Southeast Asian pharmaceutical market and accelerating its internationalization strategy for 2025 [1][2] - Insulin Glargine is recognized for its clinical advantages in stable blood sugar control and reduced hypoglycemia risk, making it a key medication in global diabetes treatment [1] - The approval aligns with the increasing diabetes prevalence in Southeast Asia, particularly in Myanmar, where insulin accessibility remains a challenge, presenting opportunities for competitive Chinese pharmaceutical companies [1] Market Strategy - The approval is a result of Tonghua Dongbao's differentiated overseas strategy, which includes a tiered market approach: collaborating with companies like Jianyou Pharmaceutical for registration in developed markets, while directly pursuing product registration and commercialization in emerging markets along the Belt and Road [2] - Since 2025, the company has achieved multiple approvals in various markets, including Nicaragua and Uzbekistan, and received GMP certification for Liraglutide in Colombia, further enhancing its overseas market presence [2] - The company's overseas revenue reached 110 million yuan in the first half of the year, surpassing the total for 2024, indicating significant growth [2] Strategic Value - Entering the Myanmar market provides multiple strategic advantages for Tonghua Dongbao, including immediate volume growth due to local medical demand and the potential to use Myanmar as a base to expand into surrounding Southeast Asian markets [3] - The experience gained from this approval will facilitate future overseas applications for other products, such as Insulin Aspart, thereby accelerating the company's global expansion [3] - With ongoing launches of various insulin products in international markets, Tonghua Dongbao is transitioning into a new phase of "dual-driven" development, supported by domestic procurement policies and breakthroughs in overseas emerging markets, leading to an 85.60% year-on-year revenue growth in the first half of the year [3]

Core Viewpoint - Tonghua Dongbao has received marketing approval for its insulin glargine injection from the Ministry of Health of the Republic of the Union of Myanmar, which is expected to enhance its international market presence and product line [2][4]. Group 1: Product Development and Market Expansion - The company focuses on research and development in diabetes and endocrine-related medications, aiming to provide comprehensive solutions for patients [2]. - Tonghua Dongbao's insulin analogs saw over 200% year-on-year sales growth in the domestic market during the first half of 2025, leveraging new procurement policies to expand market share [3]. - The company is accelerating the overseas commercialization of multiple products, with overseas market revenue reaching 110 million yuan, a nearly 187% increase year-on-year in the first half of 2025 [2][3]. Group 2: Market Demand and Demographics - As of August 2025, Myanmar has a population of approximately 51.3 million, with increasing healthcare demands driven by aging, urbanization, and rising chronic disease prevalence [3]. - The International Diabetes Federation (IDF) projects that the number of diabetes patients aged 20-79 in Myanmar will rise to 2.3658 million in 2024, with a prevalence rate of 6.4% among adults in that age group [3]. Group 3: Strategic Implications - The approval of insulin glargine is expected to enrich the company's international product line, enhance brand image, and facilitate market entry in emerging markets [4]. - The company has initiated preparatory work for product sales, although actual sales may be influenced by market demand, policy changes, and competition, introducing an element of uncertainty [4].

Core Viewpoint - Tonghua Dongbao has received approval from the Ministry of Health of the Republic of the Union of Myanmar for the marketing authorization of its product, Glargine Insulin Injection, which is expected to enhance its international market presence and product line [1][3]. Group 1: Product Development and Market Expansion - The company is focused on research and development in the diabetes and endocrine fields, providing comprehensive solutions for patients [1]. - Tonghua Dongbao aims to accelerate the commercialization of multiple products in overseas markets by the first half of 2025, with overseas revenue reaching 110 million yuan, a year-on-year increase of nearly 187% [1][2]. - The company has achieved over 200% year-on-year growth in the sales of insulin analogs in the domestic market during the first half of 2025 [2]. Group 2: Regulatory Approvals and Market Potential - The company’s Aspart Insulin BLA has been accepted by the FDA, and it is progressing with the BLA submissions for Glargine and Lispro Insulin [2]. - The approval of Glargine Insulin is expected to enhance the company's international product line and brand image, while also providing replicable experience for future market access applications [3]. - In Myanmar, the diabetes patient population aged 20-79 is projected to reach 2.3658 million in 2024, with a diabetes prevalence rate of 6.4% among adults [2].

中国能建：签署重大合同，合同金额约195.54亿元人民币 今日焦点 两市首份三季报出炉：金岭矿业前三季度净利润同比增长47% 金岭矿业披露2025年三季度报告，公司第三季度实现营业收入4.79亿元，同比增长17.78%；归属于上市 公司股东的净利润为7016.81万元，同比增长0.25%。前三季归属于上市公司股东的净利润为2.20亿元， 同比增长47.09%。 北方稀土：2025年第四季度稀土精矿交易价格调整为不含税26205元/吨，环比上涨37.13% 北方稀土公告称，根据稀土精矿定价方法及2025年第三季度稀土氧化物价格，经测算并经公司总经理办 公会审议通过，2025年第四季度稀土精矿交易价格调整为不含税26205元/吨（干量，REO=50%）， REO每增减1%、不含税价格增减524.10元/吨。 上纬新材：股票交易停牌核查完成股票10月13日复牌 上纬新材公告称，公司股票将于10月13日复牌。此前，公司因股票交易异常波动停牌核查。经核实，收 购方及实际控制人未来12个月内无资产重组计划，公司基本面未发生重大变化。但公司股价已严重脱离 基本面，存在快速下跌风险。此外，公司股票交易多次异常波动，市盈率显著 ...

Group 1 - Tibet Pharmaceutical's Zolbetuximab has been officially commercialized in the first half of this year, focusing on advanced non-small cell lung cancer with CNS metastasis [1] - The product is the first EGFR TKI designed to penetrate the blood-brain barrier, achieving 100% permeability [1] - The company is preparing for medical insurance negotiations, but the expected revenue impact for this year is minimal [1] Group 2 - Jianerkang emphasizes the importance of accounts receivable management, with dedicated sales personnel responsible for tracking and collecting payments [2] - Performance evaluations for sales staff are strictly linked to payment collection [2] - The company has a risk control specialist who organizes monthly meetings to establish collection plans and follow up on key accounts [2] Group 3 - Tonghua Dongbao has completed the first patient dosing in the Phase II clinical trial for THDBH120, showing good safety and efficacy trends [3] - The company's insulin formulation is still in preclinical research, with future updates to be disclosed as per regulations [3] Group 4 - XinNuoWei is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and competitiveness [4] - The board has approved the proposal to seek shareholder authorization for the overseas listing [4] Group 5 - Bailitiheng has received clinical trial approval for its innovative drug BL-ARC001, aimed at treating advanced solid tumors [5] - BL-ARC001 is the company's first class I innovative drug in the antibody-radiolabeled conjugate field, with potential first-in-class status [5] - The drug is expected to offer better specificity and tumor accumulation compared to traditional radiolabeled drugs [5] Group 6 - Nocare and Zenas have reached a licensing agreement for three autoimmune pipeline products, with a potential total transaction value exceeding $2 billion [6][7] - Zenas will pay up to $100 million in upfront and milestone payments, along with issuing shares to Nocare [7] - Nocare retains global rights for the oncology application of the licensed products while granting Zenas exclusive rights in specific regions [7]

Group 1 - Jieqiang Equipment has completed the acquisition of 51% stake in Shandong Carbon Seeking, which will now be included in the company's consolidated financial statements [1] - Tonghua Dongbao's insulin injection product has received marketing approval in Myanmar for diabetes treatment [1] - New Light Optoelectronics' actual controller plans to increase shareholding by 5 to 10 million yuan within six months [2] Group 2 - Far East Holdings received contracts worth 1.769 billion yuan in September [3] - Poly Developments reported a 1.84% decrease in signed sales amount in September, totaling 20.531 billion yuan [4] - ST Nuotai expects a net profit increase of 5.62% to 13.74% for Q3 2025 [7] Group 3 - Chongqing Port's controlling shareholder plans to merge with another entity, changing the controlling shareholder to Chongqing Logistics Group [9] - New Energy Company reported a 28.21% increase in cumulative power generation from January to September [11] - Dashiang Co. announced the resignation of its chairman due to personal reasons [12] Group 4 - Liao Port Co. announced the resignation of a non-executive director due to work changes [13] - Zhongzai Resources received a government subsidy of 5.33 million yuan, accounting for 23.72% of its audited net profit for 2024 [14] - Xiaoming Co. reported a sales revenue of 66.15 million yuan from chicken products in September [15] Group 5 - Tianyi Co. signed a framework contract worth 23.50 million yuan for e-business network terminal production [16] - Jingu Co. signed a strategic cooperation agreement with Ninebot Technology for lightweight materials [18] - Tianbang Foods reported a sales revenue of 634 million yuan from commodity pigs in September [20] Group 6 - Shaanxi Energy's subsidiary received an administrative penalty for safety violations, resulting in a fine of 940,000 yuan [22] - North Bay Port reported a 9% increase in cargo throughput in September [23] - Tangrenshen reported a sales revenue of 639 million yuan from pig sales in September [24] Group 7 - Dabeinong reported a sales revenue of 541 million yuan from pig sales in September [25] - Jiukang Bio obtained four medical device registration certificates [26] - Canan Co. invested 90 million yuan in structured deposits with a bank [27] Group 8 - Zhuhai Port reported a 5.44% decrease in cargo throughput in Q3 [28] - Jinli Yongmag expects a net profit increase of 157% to 179% for the first three quarters [29] - Huamao Logistics' controlling shareholder plans to increase shareholding by 64.5 to 129 million yuan [30] Group 9 - Dongjie Intelligent signed a 50 million yuan contract for intelligent warehousing in the steel industry [31] - Sais Technology signed a cooperation framework agreement with Volcano Engine for intelligent robotics [32] - Huadong Pharmaceutical's subsidiary received approval for clinical trials of a new drug targeting advanced solid tumors [34] Group 10 - TCL Technology completed the acquisition of 80% and 100% stakes in LG Display's subsidiaries for 11.088 billion yuan [34] - Shuangliang Energy won a 419 million yuan EPC project for cooling systems [36] - Ruina Intelligent announced plans for shareholders to reduce their stakes by up to 1.18% [38] Group 11 - Baodi Mining announced plans for shareholders to reduce their stakes by up to 5.45% [40] - Xinyi Technology's shareholders set the transfer price for shares at 328 yuan each [42] - Sunshine Power submitted an application for H-share listing on the Hong Kong Stock Exchange [44] Group 12 - Qisheng Technology's controlling shareholder plans to reduce their stake by up to 3.09% [46] - Wu Ming Kangde sold 30.3 million shares of Wu Ming He Lian through block trading [48] - Qiaoyin Co. announced plans for shareholders to reduce their stakes by up to 6% [49] Group 13 - Muyuan Foods reported a sales revenue of 9.066 billion yuan from commodity pigs in September [51] - Huawang Technology's shareholders plan to reduce their stakes by up to 1.1% [53] - Huaxin Xinchuang received a project notification from Lantu Automotive for display components [54] Group 14 - China Merchants Shekou reported a signed sales amount of 16.698 billion yuan in September [55] - Shao Neng Co. received approval for an antitrust review regarding a share acquisition [57] - Pengding Holdings reported a 6.21% increase in consolidated revenue in September [58] Group 15 - Ganfeng Lithium is advancing its solid-state battery commercialization and strategic investment in the energy storage sector [59]